GlassScriptPhysician profile
Kay Y Kelts
NPI 1083956932
$4,605.54
in general payments reported to CMS, 2019-2025
31 companies · $760 in 2025
The $760 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $112 · 2021: $544 · 2022: $529 · 2023: $908 · 2024: $1,253 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,922.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $597.57 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $534.18 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $458.33 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $328.30 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $320.67 | 2021-2025 | |
| Novo Nordisk INC | $313.79 | 2019-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $229.33 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.07 | 2019-2022 | |
| Glaxosmithkline, LLC. | $199.79 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $171.92 | 2019-2025 | |
| Exact Sciences Corporation | $148.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Madrigal Pharmaceuticals | $145.29 | 2024 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $97.79 | 2019-2023 | Entyvio |
| Inspire Medical Systems, INC. | $85.67 | 2025 | Inspire |
| Alexion Pharmaceuticals, INC. | $85.65 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $65.46 | 2019-2024 | Vaxneuvance, Vaxelis, Capvaxive |
| Daiichi Sankyo INC. | $63.31 | 2022-2024 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $62.33 | 2019-2025 | Eliquis |
| Amarin Pharma, INC. | $47.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $47.09 | 2022-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $44.91 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $42.31 | 2019-2020 | |
| Grifols USA, LLC | $40.02 | 2023 | Prolastin-C Liquid |
| Dexcom, INC. | $37.67 | 2023 | Dexcom G7 Gss (161) |
| Indivior INC. | $37.30 | 2019 | |
| Astellas Pharma US INC | $35.01 | 2025 | Veozah |
| Redhill Biopharma INC. | $34.41 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.46 | 2025 | Caplyta |
| Medtronic, INC. | $29.18 | 2024-2025 | Minimed 780g |
| Abbott Laboratories | $22.66 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $19.99 | 2024 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kay Kelts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.